Biotech startup pulls in $187M to make ‘multi-payload’ ADCs

Biotech startup pulls in $187M to make ‘multi-payload’ ADCs

Source: 
BioPharma Dive
snippet: 

Callio Therapeutics is debuting with an ADC technology and related programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.